Europe - FRA:93M1 - DE000A289V03 - Common Stock
The current stock price of 93M1.DE is 18.25 EUR. In the past month the price increased by 1.96%. In the past year, price decreased by -23.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 53.15 | 703.22B | ||
| LLY.DE | ELI LILLY & CO | 53.13 | 703.03B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.56 | 440.12B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.17 | 393.33B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.74 | 384.13B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 13.86 | 237.60B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.97 | 239.54B | ||
| SNW.DE | SANOFI | 14.26 | 213.75B | ||
| SAN.PA | SANOFI | 14.24 | 213.49B | ||
| 1SAN.MI | SANOFI | 14.19 | 212.63B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 14.13 | 207.14B | ||
| NOT.DE | NOVARTIS AG-REG | 14.16 | 207.52B |
MPH Health Care AG is an investment company, which engages in the acquisition and development of companies and shares in companies from the healthcare industry. The company is headquartered in Berlin, Berlin and currently employs 2 full-time employees. The company went IPO on 2009-01-01. The firm focuses on the purchase, development and sale of companies and shares in companies from the healthcare market. The firm's portfolio comprises HAEMATO AG, M1 Kliniken AG and MPH Ventures. HAEMATO AG is a pharmaceutical company that offers generics for the therapies of cancer, human immunodeficiency virus (HIV) and other chronic diseases. M1 Kliniken AG focuses on the medicinal beauty market and develops and sells pharmaceutical and medical products and services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. MPH Ventures operates as venture capitalist and invests in Pharmigon GmbH, a company specialized in cytostatic admixture and concomitant medications, as well as in the real estate company CR Capital Real Estate AG.
MPH HEALTH CARE AG KONV
Gruenauer Strasse 5
Berlin BERLIN DE
Employees: 2
Phone: 4930863214560
MPH Health Care AG is an investment company, which engages in the acquisition and development of companies and shares in companies from the healthcare industry. The company is headquartered in Berlin, Berlin and currently employs 2 full-time employees. The company went IPO on 2009-01-01. The firm focuses on the purchase, development and sale of companies and shares in companies from the healthcare market. The firm's portfolio comprises HAEMATO AG, M1 Kliniken AG and MPH Ventures. HAEMATO AG is a pharmaceutical company that offers generics for the therapies of cancer, human immunodeficiency virus (HIV) and other chronic diseases. M1 Kliniken AG focuses on the medicinal beauty market and develops and sells pharmaceutical and medical products and services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. MPH Ventures operates as venture capitalist and invests in Pharmigon GmbH, a company specialized in cytostatic admixture and concomitant medications, as well as in the real estate company CR Capital Real Estate AG.
The current stock price of 93M1.DE is 18.25 EUR. The price decreased by -1.62% in the last trading session.
MPH HEALTH CARE AG KONV (93M1.DE) has a dividend yield of 6.65%. The yearly dividend amount is currently 0.
93M1.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
You can find the ownership structure of MPH HEALTH CARE AG KONV (93M1.DE) on the Ownership tab.
ChartMill assigns a technical rating of 2 / 10 to 93M1.DE. When comparing the yearly performance of all stocks, 93M1.DE is a bad performer in the overall market: 90.65% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to 93M1.DE. The financial health of 93M1.DE is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months 93M1.DE reported a non-GAAP Earnings per Share(EPS) of -26.91. The EPS decreased by -196.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.66% | ||
| ROE | -56.18% | ||
| Debt/Equity | 0.02 |